The aim of the study is to demonstrate that conduction system pacing (CSP) can preserve a normal ventricular function compared to right ventricular apical pacing (RVAP) in patients with pre-implant preserved left ventricular ejection fraction (LVEF) and a high burden of expected ventricular pacing due to atrioventricular conduction block (AV block). After informed consent signature, patients with high degree AV block and normal LVEF will be randomized to permanent pacemaker stimulation with CSP vs RVAP. All the patients have a complete evaluation before the procedure and at 3 and 6 months follow-up.
The STAY trial (Conduction System sTimulation to Avoid left ventricle dYsfunction) is a single-center, prospective, randomized, parallel, controlled study, comparing mid-term outcomes in a population undergoing pacemaker implantation due to a high degree atrio-ventricular block (AVB). The study was approved by the Hospital Ethics Committee, in accordance with the Declaration of Helsinki. All patients signed informed consent and were implanted between September 2019 until December 2022 in a 1:1 randomized fashion to conventional RVAP vs CSP (HBS or LBBS). Randomization was performed during the pre-procedural antibiotic infusion. All the patients have a complete evaluation before the procedure and at 3 and 6 months follow-up, including demographic and clinical characteristics, physical examination, twelve-lead ECG, Minnesota score (MLWHFQ), and blood test with NT-ProBNP determination. Patients also have a transthoracic echography before the procedure and at 6 months follow-up. At 6 months echocardiographic and clinical data will be compared.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
75
Implantation of pacemaker with conduction system pacing or right ventricular apical pacing
Hospital del Mar
Barcelona, Spain
Delta-LVEF at 6 months
Change in LVEF in each group at 6 months vs baseline LVEF
Time frame: 6 months
Delta-LVEDD at 6 months
Change in Left ventricular end diastolic diameter (LVEDD) in each group at 6 months vs baseline LVEDD
Time frame: 6 months
Delta-MLWHFQ (Minnesota score) at 6 months
Change in MLWHFQ score in each group at 6 months vs baseline MLWHFQ score. The MLWHFQ score is obtained by using a questionnaire of 21 aspects. It depicts how heart failure affected the daily life of the patients during the last month previous to the questionnaire. Each question can be scored from 0 ("No" effect) to 5 ("Very much" effect)
Time frame: 6 months
Delta-New York Heart Association (NYHA) class at 6 months
Change in NYHA class in each group at 6 months vs baseline NYHA class. NYHA class places patients in one of four categories based on limitations of physical activity: * I: No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation or shortness of breath. * II: Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, shortness of breath or chest pain. * III: Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, shortness of breath or chest pain. * IV: Symptoms of heart failure at rest. Any physical activity causes further discomfort.
Time frame: 6 months
Delta-NTProBNP at 6 months
Change in NTProBNP levels in each group at 6 months vs baseline NTProBNP levels
Time frame: 6 months
Readmissions due to heart failure
Number of readmissions due to heart failure in each group during follow-up
Time frame: 6 months
New onset Atrial fibrillation
Number of new-onset atrial fibrillation episodes in each group during follow-up
Time frame: 6 months
Mortality
All-cause Mortality in each group during follow-up
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.